Barriers to Oncology Biosimilars Uptake in the United States

Oncologist - United States
doi 10.1634/theoncologist.2018-0066
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Biosimilars: Barriers and Opportunities to Market Access in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Barriers and Facilitators to Cochlear Implant Uptake in Australia and the United Kingdom

Ear and Hearing
OtorhinolaryngologySpeechHearing
2020English

Value and Payment for Oncology in the United States

Annales Pharmaceutiques Francaises
PharmacologyPharmaceutical Science
2013English

The Role of Biosimilars in Value-Based Oncology Care

Cancer Management and Research
Oncology
2018English

Barriers Over Time to Full Implementation of Health Information Exchange in the United States

JMIR Medical Informatics
2014English

Improving College Access in the United States: Barriers and Policy Responses

2015English

Gender Disparities in Radiation Oncology Residency Programs in the United States- Current Status

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Reply to ‘Biosimilars: A Position Paper of the European Society for Medical Oncology, With Particular Reference to Oncology Prescribers’

ESMO Open
Cancer ResearchOncology
2017English

Supply and Demand for Radiation Oncology in the United States: Updated Projections for 2015 to 2025

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy